{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:02:55Z","timestamp":1791925375488,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370326"],"award-info":[{"award-number":["81370326"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81641005"],"award-info":[{"award-number":["81641005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Municipal Science and Technology Project","award":["Z181100001718200"],"award-info":[{"award-number":["Z181100001718200"]}]},{"name":"National Precision Medical Research Program of China","award":["2016YFC0905602"],"award-info":[{"award-number":["2016YFC0905602"]}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7202168"],"award-info":[{"award-number":["7202168"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary veno-occlusive disease (PVOD) is a rare condition with poor prognosis, and lung transplantation is recommended as the only curative therapy. The role of pulmonary arterial hypertension targeted therapy in PVOD remains controversial, and long-term effects of targeted therapy have been rarely reported. This study aims to retrospectively evaluate the role of targeted therapy in PVOD patients and the long-term outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PVOD patients with good responses to targeted therapies were analyzed, and data pre- and post- targeted therapies were compared. An overview of the effects of targeted therapies on PVOD patients was also conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five genetically or histologically confirmed PVOD patients received targeted therapies and showed good responses. Their mean pulmonary arterial pressure by right heart catheterization was 62.0\u2009\u00b1\u200911.7\u2009mmHg. Two receiving monotherapy got stabilized, and three receiving sequential combination therapy got improved, cardiac function and exercise capacity significantly improved after treatments. No pulmonary edema occurred. The mean time from the first targeted therapy to the last follow up was 39.3\u2009months, and the longest was 9\u2009years. A systematic review regarding the effects of targeted therapies on PVOD patients indicated majorities of patients got hemodynamics or 6-min walk distance improved, and 26.7% patients developed pulmonary edema. The interval from targeted drugs use to death ranged from 71\u2009min to over 4\u2009years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Cautious use of targeted therapy could safely and effectively improve or stabilize hemodynamics and exercise capacity of some patients without any complications. PVOD patients could live longer than expected.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12890-019-1031-3","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T18:03:25Z","timestamp":1576778605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?"],"prefix":"10.1186","volume":"19","author":[{"given":"Qin","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-6306","authenticated-orcid":false,"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"key":"1031_CR1","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1183\/13993003.00026-2016","volume":"47","author":"D Montani","year":"2016","unstructured":"Montani D, Lau EM, Dorfm\u00fcller P, Girerd B, Ja\u00efs X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47:1518\u201334.","journal-title":"Eur Respir J"},{"key":"1031_CR2","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1183\/09031936.00017809","volume":"34","author":"D Montani","year":"2009","unstructured":"Montani D, Ja\u00efs X, Price LC, Achouh L, Degano B, Mercier O, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J. 2009;34:1348\u201356.","journal-title":"Eur Respir J"},{"key":"1031_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.resinv.2018.10.004","volume":"57","author":"A Ogawa","year":"2018","unstructured":"Ogawa A, Sakao S, Tanabe N, Matsubara H, Tatsumi K. Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a systematic review. Respir Investig. 2018;57:183\u201390.","journal-title":"Respir Investig"},{"key":"1031_CR4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46:903\u201375.","journal-title":"Eur Respir J"},{"key":"1031_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5603\/ARM.2018.0021","volume":"86","author":"M Szturmowicz","year":"2018","unstructured":"Szturmowicz M, Kacprzak A, Szo\u0142kowska M, Burakowska B, Szczepulska E, Ku\u015b J. Pulmonary veno-occlusive disease: pathogenesis, risk factors, clinical features and diagnostic algorithm - state of the art. Adv Respir Med. 2018;86:131\u201341.","journal-title":"Adv Respir Med"},{"key":"1031_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pupt.2017.01.012","volume":"43","author":"Y Tang","year":"2017","unstructured":"Tang Y, Yao L, Liu Z, Ma X, Luo Q, Zhao Z, et al. Effect of calcium channel blockers evaluated by cardiopulmonary exercise testing in idiopathic pulmonary arterial hypertension responding to acute pulmonary vasoreactivity testing. Pulm Pharmacol Ther. 2017;43:26\u201331.","journal-title":"Pulm Pharmacol Ther"},{"key":"1031_CR7","doi-asserted-by":"crossref","first-page":"e005037","DOI":"10.1161\/JAHA.116.005037","volume":"6","author":"Y Tang","year":"2017","unstructured":"Tang Y, Luo Q, Liu Z, Ma X, Zhao Z, Huang Z, et al. Oxygen uptake efficiency slope predicts poor outcome in patients with idiopathic pulmonary arterial hypertension. J Am Heart Assoc. 2017;6:e005037.","journal-title":"J Am Heart Assoc"},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.rmed.2018.01.003","volume":"135","author":"Y Tang","year":"2018","unstructured":"Tang Y, Yao L, Liu Z, Xie W, Ma X, Luo Q, et al. Peak circulatory power is a strong prognostic factor in patients with idiopathic pulmonary arterial hypertension. Respir Med. 2018;135:29\u201334.","journal-title":"Respir Med"},{"key":"1031_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.hrtlng.2018.05.002","volume":"47","author":"X Yu","year":"2018","unstructured":"Yu X, Luo Q, Liu Z, Zhao Z, Zhao Q, An C, et al. Prevalence of iron deficiency in different subtypes of pulmonary hypertension. Heart Lung. 2018;47:308\u201313.","journal-title":"Heart Lung"},{"key":"1031_CR10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1253\/circj.CJ-11-0973","volume":"76","author":"A Ogawa","year":"2012","unstructured":"Ogawa A, Miyaji K, Yamadori I, Shinno Y, Miura A, Kusano KF, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circ J. 2012;76:1729\u201336.","journal-title":"Circ J"},{"key":"1031_CR11","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1378\/chest.96.4.784","volume":"96","author":"K Jones","year":"1989","unstructured":"Jones K, Higenbottam T, Wallwork J. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest. 1989;96:784\u20139.","journal-title":"Chest"},{"key":"1031_CR12","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1378\/chest.108.6.1754","volume":"108","author":"LL Davis","year":"1995","unstructured":"Davis LL, de Boisblanc BP, Glynn CE, Ramirez C, Summer WR. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest. 1995;108:1754\u20136.","journal-title":"Chest"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1378\/chest.113.1.237","volume":"113","author":"SM Palmer","year":"1998","unstructured":"Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 1998;113:237\u201340.","journal-title":"Chest"},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0954-6111(99)90079-3","volume":"93","author":"MM Hoeper","year":"1999","unstructured":"Hoeper MM, Eschenbruch C, Zink-Wohlfart C, Schulz A, Markworth S, Pohl K, et al. Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease. Respir Med. 1999;93:62\u20134.","journal-title":"Respir Med"},{"key":"1031_CR15","first-page":"1671","volume":"118","author":"BW Holcomb Jr","year":"2000","unstructured":"Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. Chest. 2000;118:1671\u20139.","journal-title":"Chest"},{"key":"1031_CR16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1378\/chest.122.3.1096","volume":"122","author":"H Okumura","year":"2002","unstructured":"Okumura H, Nagaya N, Kyotani S, Sakamaki F, Nakanishi N, Fukuhara S, et al. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease. Chest. 2002;122:1096\u20138.","journal-title":"Chest"},{"key":"1031_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1590\/S0100-879X2005000200006","volume":"38","author":"AC Barreto","year":"2005","unstructured":"Barreto AC, Franchi SM, Castro CR, Lopes AA. One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. Braz J Med Biol Res. 2005;38:185\u201395.","journal-title":"Braz J Med Biol Res"},{"key":"1031_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.hlc.2005.07.002","volume":"15","author":"T Kuroda","year":"2006","unstructured":"Kuroda T, Hirota H, Masaki M, Sugiyama S, Oshima Y, Terai K, et al. Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease. Heart Lung Circ. 2006;15:139\u201342.","journal-title":"Heart Lung Circ"},{"key":"1031_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1183\/09031936.00054407","volume":"32","author":"MJ Overbeek","year":"2008","unstructured":"Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008;32:232\u20135.","journal-title":"Eur Respir J"},{"key":"1031_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1590\/S1806-37132008000900015","volume":"34","author":"CE Barboza","year":"2008","unstructured":"Barboza CE, Jardim CV, Hovnanian AL, Dias BA, Souza R. Pulmonary veno-occlusive disease: diagnostic and therapeutic alternatives. J Bras Pneumol. 2008;34:749\u201352.","journal-title":"J Bras Pneumol"},{"key":"1031_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1183\/09031936.00102609","volume":"34","author":"D Montani","year":"2009","unstructured":"Montani D, Ja\u00efs X, Dorfmuller P, Simonneau G, Sitbon O, Humbert M. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J. 2009;34:1204\u20136.","journal-title":"Eur Respir J"},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1183\/09059180.00003909","volume":"18","author":"M Palazzini","year":"2009","unstructured":"Palazzini M, Manes A. Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension. Eur Respir Rev. 2009;18:177\u201380.","journal-title":"Eur Respir Rev"},{"key":"1031_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1753465812468042","volume":"7","author":"E Sourla","year":"2013","unstructured":"Sourla E, Paspala A, Boutou A, Kontou P, Stanopoulos I, Pitsiou G. A case of pulmonary veno-occlusive disease: diagnostic dilemmas and therapeutic challenges. Ther Adv Respir Dis. 2013;7:119\u201323.","journal-title":"Ther Adv Respir Dis"},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/CCRR.1000285","volume":"2","author":"A El-Gammal","year":"2016","unstructured":"El-Gammal A, Alsudairi S, Alwohaibi R, Aldihan W, Alsufiani S, Fadel R, et al. Pulmonary Veno-occlusive disease: a case report and review of literature. Clin Case Rep Rev. 2016;2:1\u20134.","journal-title":"Clin Case Rep Rev"},{"key":"1031_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.recesp.2016.07.003","volume":"70","author":"CI Chamorro Fern\u00e1ndez","year":"2017","unstructured":"Chamorro Fern\u00e1ndez CI, Garc\u00e9s Cabello P, P\u00e9rez Mateos R, S\u00e1nchez Soriano RM, Ferrando Siscar C, Quezada Loaiza CA. The first experience of pulmonary Veno-occlusive disease treatment with Macitentan and Sildenafil. Rev Esp Cardiol (Engl Ed). 2017;70:396\u20137.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"1031_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12931-018-0900-2","volume":"19","author":"L Liang","year":"2018","unstructured":"Liang L, Su H, Ma X, Zhang R. Good response to PAH-targeted drugs in a PVOD patient carrying Biallelic EIF2AK4 mutation. Respir Res. 2018;19:192.","journal-title":"Respir Res"},{"key":"1031_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/MD.0b013e31818193bb","volume":"87","author":"D Montani","year":"2008","unstructured":"Montani D, Achouh L, Dorfm\u00fcller P, Le Pavec J, Sztrymf B, Tch\u00e9rakian C, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008;87:220\u201333.","journal-title":"Medicine (Baltimore)"},{"key":"1031_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ng.2844","volume":"46","author":"M Eyries","year":"2014","unstructured":"Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46:65\u20139.","journal-title":"Nat Genet"},{"key":"1031_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2213-2600(16)30438-6","volume":"5","author":"D Montani","year":"2017","unstructured":"Montani D, Girerd B, Ja\u00efs X, Levy M, Amar D, Savale L, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med. 2017;5:125\u201334.","journal-title":"Lancet Respir Med"},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"e503","DOI":"10.1161\/CIRCULATIONAHA.111.088450","volume":"125","author":"K Matsushita","year":"2012","unstructured":"Matsushita K, Kanna M, Yazawa T, Shimizu S, Nitta M, Takamizawa T, et al. Long-term survivor with pulmonary veno-occlusive disease. Circulation. 2012;125:e503\u20136.","journal-title":"Circulation"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-1031-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-019-1031-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-1031-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:06:46Z","timestamp":1665274006000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-019-1031-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1186\/s12890-019-1031-3","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of Fuwai Hospital and adhered to the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}